Real-World Management of AEs with ALK Inhibitors

EP: 1.Sarah’s Journey With ALK+ Metastatic NSCLC

EP: 2.Patient Education: Preparing Patients for ALK Inhibitor Treatment

EP: 3.Strategies for Managing Neurotoxic AEs With Lorlatinib

EP: 4.Lorlatinib AE Management: Weight Gain and GI Issues

EP: 5.Multidisciplinary Approach to AE Management With Lorlatinib

Now Viewing

EP: 6.Real-World Management of AEs with ALK Inhibitors

EP: 7.Eleanor’s Journey With KRAS+ Metastatic NSCLC

EP: 8.Educating Patients About AEs Associated With KRAS-Targeted Therapies in NSCLC

EP: 9.Managing AEs Associated With Adagrasib for NSCLC

EP: 10.Goals of Care: in mNSCLC Balancing QOL and Treatment Maintenance

Video content above is prompted by the following:

• Based on your experience, how does the adverse event profile of lorlatinib compare to those of other ALK inhibitors like alectinib or brigatinib?
• Are there any unique challenges or benefits you've observed?